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ABSTRACT 
Background: Many people living with chronic Hepatitis C Virus (HCV) have seen delays 
in accessing treatment or been denied entirely due to Medicaid restrictions requiring patients to 
meet certain criteria prior to receiving approval for medication pre-authorization. 
Methods: This study identified a cohort of Medicaid-insured patients with chronic HCV 
infection within New Orleans, LA. Patient medical records were reviewed and information 
regarding HCV care was gathered. This study sought to determine the degree to which HCV care 
was delayed for this population and describe common reasons for prior-authorization denials for 
direct-acting antiviral (DAA) medications. 
Results: For this population of Medicaid-insured patients with HCV RNA assay-confirmed 
chronic infection, the average number of days it took to reach a specialist was three-times greater 
than the number of days it took to reach a primary care physician. After attending an appointment 
with a specialist to seek HCV care, patients experienced wait periods of an average of 150 days 
before being deemed eligible for treatment per Medicaid requirements. After being deemed 
eligible for treatment, patients experienced an average wait period of 194.4 days to initiation of 
treatment, with low fibrosis status being cited as the most common reason for treatment delay. 
Conclusion: This population of Medicaid-insured patients in New Orleans, LA with 
chronic HCV infection experienced delays in treatment related to reduced accessibility of a 
specialist who was eligible to request DAA prior-authorization. Prior-authorization was most 
frequently denied based on low fibrosis status or recent alcohol/drug use. 
Keywords:  Health inequities; hepatitis C; Medicaid; direct-acting antiviral 
 
INTRODUCTION  
In 2015, an estimated 3.5 million people in the United States were chronically infected 
with the hepatitis C virus (HCV), with the potential for underestimation indicating that the true 
prevalence could be much greater (Edlin et al., 2015). An important public health implication of 
untreated chronic and progressive HCV infection is the potential for further transmission of the 
virus. Chronic infection leads to increased morbidity and mortality, including potential cirrhosis, 
end-stage liver disease, and hepatocellular carcinoma (Liang et al., 2000). Fortunately, recent 
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pharmacologic innovations in the form of direct-acting antivirals (DAA) have made safe and 
highly effective eradication of HCV possible (Afdhal et al., 2014). A study of Veterans Affairs 
patients documented that progression to cirrhosis and a decompensation event in the setting of 
HCV infection may occur more quickly than previously thought (Butt et al., 2015). Moreover, 
sustained virological response following antiviral treatment has been shown to decrease liver-
related morbidity and all-cause mortality among patients with chronic HCV infection, even those 
with advanced hepatic fibrosis (van der Meer et al., 2012). As a result, the current guidelines 
recommend treatment of all genotypes of HCV with DAAs (AASLD/IDSA, 2017). 
Since their advent in 2013, the US Food and Drug Administration has approved numerous 
types of DAAs for the treatment of HCV (FDA, 2017). However, the high costs of DAAs have 
caused both private and public insurers in the US to limit access to these medications (Trooskin et 
al., 2015). Like other insurers, Medicaid has set specific reimbursement criteria such as 
consultation with a specialist, sobriety from alcohol and illicit drugs, and evidence of advanced 
fibrosis or cirrhosis (Barua et al., 2015). These Medicaid restrictions vary from state to state (Barua 
et al., 2015). Multiple studies have shown the negative impact of these Medicaid restrictions. A 
prospective cohort study across four Northeast states showed significantly higher rates of DAA 
absolute denial among those insured by Medicaid (46%) compared to those insured by Medicare 
(5%) and by commercial insurance (10%) (Re et al., 2016). Another cohort study in Southeast 
Michigan yielded similar results (Bourgi, et al., 2016). 
From 2015 to May 2018, Louisiana Medicaid required abstinence from illicit substances 
and alcohol use for 12 months, one of only two states to do so, with other states ranging from no 
requirements to 6 months of abstinence (Barua et al., 2015). Prescribing physicians were required 
to provide proof of abstinence with a negative urine drug screen and blood alcohol level within 30 
days of initiating treatment in addition to conducting random drug and alcohol screenings every 
30 days throughout the course of treatment (Louisiana Department of Health, 2016). At that time, 
Louisiana was one of 14 states that only permitted physicians within the specialties of 
gastroenterology, hepatology, or infectious disease to request DAA pre-authorization (Barua et al., 
2015). Louisiana Medicaid also required that the patient met criteria for advanced fibrosis or 
cirrhosis prior to DAA pre-authorization (Louisiana Department of Health, 2016). 
 Heterogeneity of Medicaid pre-authorization criteria for DAAs between states has led to 
confusion for policy-makers and providers. Anecdotally, providers are well-aware of institutional 
and policy barriers to accessing treatment for their patients, though there is a paucity of published 
data regarding the impact of Medicaid restrictions and reasons for treatment denial and delay at 
the state level. In this study, medical records of Medicaid-insured patients with chronic HCV 
infection within New Orleans, LA were reviewed to better understand their clinical course and 
evaluate the effects of restrictive Medicaid reimbursement criteria. It was hypothesized that 
Louisiana’s restrictive Medicaid reimbursement criteria would create considerable barriers to 
treatment and cause delays in treatment for patients medically indicated for DAA treatment. 
 
METHODS 
Study patients were selected retrospectively from a pool of patients with chronic HCV 
infection within the treatment cascade of “Acacia NOLA,” a student-run HCV screening and 
treatment program in New Orleans, LA. Program sites were primarily located at homeless shelters 
and substance abuse treatment centers across the city. Patients were initially included if they 
screened antibody positive for HCV and were referred for further evaluation and treatment by 
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Acacia NOLA between March 1, 2015 (inception of Acacia NOLA) and June 30, 2018 (conclusion 
of study period). Included patients were further refined to those who had been scheduled for an 
appointment with an HCV specialist after completing the necessary evaluation for referral, 
including a quantitative HCV RNA screen.   
 Primary outcomes were the average number of days to attain each step in the treatment 
process, including attending a specialist appointment, completing eligibility for DAA access, and 
starting treatment. Secondary outcomes included reasons for DAA eligibility delay and reasons 
for pre-authorization denial, as detailed in provider notes. Information about achievement along 
the treatment cascade was obtained by reviewing the electronic medical records (EMR) of both a 
local federally qualified health center (FQHC) and a local community hospital to which Acacia 
NOLA refers its patients. Data gathered from the FQHC included dates of scheduled primary care 
physician (PCP) appointments and dates of attended PCP appointments. These dates were used to 
calculate average number of days to access a PCP following a positive HCV antibody screen as a 
baseline measure of access to physician services. Average time in days to PCP appointments was 
compared with average time in days to specialist appointments.  
 Dates of scheduled viral hepatitis clinic (VHC) appointments with a specialist, dates of 
attended VHC appointments, reasons for pre-eligibility delays, reasons for post-eligibility delays, 
dates of treatment initiation, and dates of treatment completion were gathered from the local 
community hospital EMR. The dates were used to calculate the number of days between each step 
of the treatment cascade required by Medicaid to describe a care timeline for this patient 
population. Patients who completed a treatment eligibility workup with a PCP comprised the 
“VHC eligible” cohort, while those attending at least one VHC appointment were defined as “VHC 
attained.” Pre-eligibility delays were defined as the amount of time in days between first VHC 
appointment and being deemed eligible to apply to Medicaid for treatment. Patients whose DAA 
application to Medicaid was submitted during their first clinic appointment served as a baseline. 
Post-eligibility delays were defined as the amount of time in days between being deemed eligible 
to apply to Medicaid for treatment by a specialist and treatment initiation, with 21 days from 
eligibility to initiation serving as a baseline. Reasons for pre- and post-eligibility delays as 
described by providers were documented. Patient demographics and self-described characteristics 
were extracted from Acacia NOLA’s preliminary intake survey of clients during initial antibody 
screening session. The study was approved by the Tulane University Institutional Review Board. 
 
RESULTS 
Demographics and self-reported characteristics 
Between March 1, 2015 and June 30, 2018, 99 patients completed eligibility requirements 
for HCV specialist referral and were included in this study. These patients were confirmed to be 
living with chronic HCV infection by quantitative RNA assay and were scheduled for a VHC 
appointment. Of this group, 38 (38.4%) attended at least one VHC appointment (VHC attained) 
over the study period while the remaining 61 (61.7%) did not (VHC eligible). Patient 
demographics were described by VHC attainment status (Table 1). Self-reported prior experience 
with healthcare, perceived barriers to accessing care, and risk factors were assessed for differences 
between ‘VHC eligible’ and ‘VHC attained’ sub-groups (Table 2). There was a high awareness of 
HCV status at intake, with 53.5% of clients previously knowing their status. Just 17% of patients 
reported having a personal PCP upon intake, though 88% of patients reported having tried to access 
healthcare previously. Patients attending at least one VHC appointment were less likely to report 
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distrust of the healthcare system and more likely to perceive incarceration as a barrier to accessing 
healthcare. Otherwise, no significant differences exist between subgroups. 
 
 
     aTx = treatment  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Demographics  
Testing site type VHC Eligible VHC Attained Total 
Figure 1. Attainment and associated delays along the HCV treatment cascade.  
Eligible for 
specialist care 
(n=99)
Did not attend VHC 
(n=61)
Attended at least 1 
VHC appt
(n = 38)
No eligibility delays
(n = 15)
No tx access delays 
(n= 3) 
Tx access delays
(n = 12)
Eligibility delays
(n = 23)
Completed 
eligibility (n = 9) 
No tx access delays 
(n = 3)
Tx access delays 
(n=6)
Medicaid application       
submitted 
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 n % n % n 
Homeless 31 62.0% 19 38.0% 50 
SATCa 29 63.0% 17 37.0% 46 
Community 1 33.3% 2 66.7% 3 
Total 61 61.6% 38 38.4% 99 
      
Race       
White  42 65.6% 22 34.4% 64 
Black 17 51.5% 16 48.5% 33 
Hispanic 1 100.0% 0 0.0% 1 
Native American 1 100.0% 0 0.0% 1 
Total 61 61.6% 38 38.4% 99 
      
Gender       
Male  49 59.0% 34 41.0% 83 
Female  12 75.0% 4 25.0% 16 
Total 61 61.6% 38 38.4% 99 
 aSATC = substance abuse treatment centers 
 
Primary outcomes  
58.6% of patients (n = 58) were seen by a PCP at a local FQHC, at an average of 60 days 
after initial screening (Table 3). 65.8% of the VHC attained subgroup (n=25) were seen by a PCP 
at an average of 57 days post-antibody screening, while 54.1% of the VHC eligible group were 
seen by a PCP (n=33). Average time to viral RNA confirmation and ultrasound (US) were 87 days 
and 89 days, respectively. For those attending one VHC appointment, average time to RNA testing 
and ultrasound were 96 and 94 days, respectively. Average time from HCV screening to scheduled 
VHC appointment was nearly seven months (218 days). Average time to first VHC appointment 
for the 38 achieving this cascade level was 196 days from initial antibody screen, while average 
time to scheduled VHC appointment was 190 days.  
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Table 2. Self-reported characteristics by VHC status 
 VHC Eligible VHC Attained  Total p-value 
 n Ave  n Ave n Ave 
 
Age 56 42.6 37 45.6 93 43.8 
 
 
Prior access to healthcare (HC) n % yes  n % yes  n % yes   
   Previous HIV test 60 91.7% 36 100.0% 96 94.8%  
   Previous HCV test 59 78.0% 37 78.4% 96 78.1%  
   Previous HCV antibody + 38 92.1% 24 75.0% 62 85.5%  
   Previous treatment  13 30.8% 9 66.7% 22 45.5%  
   Insurance  26 76.9% 16 75.0% 42 76.2%  
   PCP 26 23.1% 16 6.3% 42 16.7%  
   Accessed HC previously 39 92.3% 19 78.9% 58 87.9%  
  
Self-reported barriers to HC access 
      Distrust  40 25.0% 19 0.0% 59 16.9% * 
      Financial 44 59.1% 25 60.0% 69 59.4%  
      Drugs 41 46.3% 19 31.6% 60 41.7%  
      Alcohol 39 17.9% 19 10.5% 58 15.5%  
      Transportation 40 42.5% 22 50.0% 62 45.2%  
      Incarceration 39 0.0% 20 15.0% 59 5.1% * 
      None 48 22.9% 26 30.8% 74 25.7%  
  
History of   
      Blood splash 61 27.9% 38 47.4% 99 35.4%  
      Organ transplant 61 0.0% 38 0.0% 99 0.0%  
      Alcohol use 61 47.5% 38 55.3% 99 50.5%  
      Substance  61 63.9% 38 73.7% 99 67.7%  
      Tattoo 61 77.0% 38 84.2% 99 79.8%  
      Amateur tattoo 32 25.0% 18 33.3% 50 28.0%  
      Jail or prison 61 93.4% 38 89.5% 99 91.9%  
      Jail 45 86.7% 21 100.0% 66 90.9%  
      Prison 45 42.2% 21 47.6% 66 43.9%  
      Blood transfusion 61 18.0% 38 7.9% 99 14.1%  
      Intravenous drug use (IVDU) 61 67.2% 38 78.9% 99 71.7%  
      Shared injection equipment 45 46.7% 21 71.4% 66 54.5%  
      Diagnosed psychiatric condition  61 31.1% 38 28.9% 99 30.3%  
      Schizophrenia 45 4.4% 21 0.0% 66 3.0%  
      Depression 45 31.1% 21 19.0% 66 27.3%  
      Bipolar 45 13.3% 21 9.5% 66 12.1%  
      Anxiety 45 20.0% 21 19.0% 66 19.7%  
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      ADHD 45 2.2% 21 0.0% 66 1.5%  
*p<0.05      **p<0.01 
 
Secondary outcomes 
Pre-eligibility delays were defined as the amount of time between first VHC appointment 
and being deemed eligible to apply to Medicaid for treatment. Clients completing eligibility during 
their first VHC appointment (n=15), served as a baseline, with any additional days between first 
VHC and being deemed eligible considered delays (Figure 1). 23 patients experienced pre-
eligibility delays, with incomplete lab work or recent ultrasound cited as the most common reason 
for deferring Medicaid application (Table 4). Positive urine drug or EtOH screen or self-reported 
drug or alcohol use were the next most commonly cited reasons. Post-eligibility delays were 
defined as the amount of time between being deemed eligible to apply to Medicaid for treatment 
and the actual day of treatment initiation, with 21 days deemed “no delay.” Low fibrosis score was 
the most commonly cited reason for application denial, delaying clients an average of 283 days 
(Table 5). Insurer preferences for one medication regimen over that initially prescribed by the 
provider delayed two patients by an average of 82.5 days.  
 
Table 3. Time to various levels of care cascade (days)  
 VHC Eligible & Attained VHC Attained 
Time to  n 
Average 
(days) St Dev n 
Average 
(days) St dev 
    1st PCP appt  58 60 104 25 57 130 
    RNA  83 87 141.4 35 96 144.4 
    US  68 89 106.3 34 94 109.9 
    Scheduled VHC appt  99 218 154.2 38 190 141.6 
    1st VHC appt    38 196 144 
 
Table 4. Pre-eligibility delays by reason      
Reason  
n 
Completed 
txa (n) 
Average delay 
(days) 
    Lost to follow up  1 1 448 
    Alcohol useb  3 1 126 
    Drug usec  6 0  
    Repeat lab work/US  1 0  
    Incomplete lab work/US  13 3 110 
Total 24 5 150 
a  Tx = treatment 
b  Positive EtOH screen or self-reported alcohol use in past 6 months  
c  Positive urine drugs screen (UDS) or self-reported drug use in past 6 months  
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Table 5. Post-eligibility delays by reason   
Reason  
n 
Completed txa 
(n) 
Average 
delays (days) 
    Drug useb  2 1 453 
    Lost to follow up  2 0 
 
    Low fibrosis score  10 1 283 
    Repeat lab work/US  2 1 71 
    Insurance preferences  2 2 82.5 
Total 18 5 194.4 
a  Tx = treatment 
b  Positive urine drugs screen (UDS) or self-reported drug use in past 6 months  
 
DISCUSSION 
This vulnerable population of people experiencing homelessness and undergoing substance 
abuse treatment faced significant barriers to accessing HCV treatment. High attrition along the 
care cascade as evidenced by less than half of eligible patients reaching a specialist, a high rate of 
Medicaid DAA application denials, and significant overall time to reaching treatment initiation 
were hallmarks of these patients’ experiences accessing HCV treatment. Along almost every stage 
of the care cascade, patients experienced institutional and policy roadblocks that made achieving 
sustained virological response (SVR) less and less likely. Given high rates of self-described 
barriers to accessing healthcare reported by this population, additional regulatory restrictions are 
particularly onerous for this group. 
Provider restriction 
Significant discrepancies in access to a PCP and specialist were found for this 
disadvantaged population. Average time to see a specialist was over three times longer than that 
to see a PCP. Further, those patients that were scheduled to a see a specialist sooner were more 
likely to attend the appointment. Given the indigent nature of this vulnerable population, rapid 
access to a provider was a key element to success along the care cascade. During the majority of 
the study period, only a specialist in the fields of infectious disease, gastroenterology, or 
hepatology was able to submit a DAA prior-authorization application to Medicaid (Louisiana 
Department of Health, 2016). Given the high safety profile and effectiveness of DAAs, the medical 
necessity of restricting dispensing power has been criticized. A number of prospective studies have 
compared DAA treatment prescribed by primary care physicians and nurse-practitioners at 
community-level clinics to those prescribed by specialists at academic HCV clinics. Results 
revealed high rates of SVR and low rates of adverse effects in both groups (Arora et al., 2011; 
Kattakuzhy et al., 2017). Given the significant attrition of this population in the time frame of 
referral from PCP to specialist, it is likely that this requirement decreased access to timely, 
efficacious HCV treatment.  
Liver fibrosis 
A low fibrosis score was the most common reason the patients in this study experienced 
considerable post-eligibility delays. Medicaid’s reimbursement criteria require patients to have 
advanced fibrosis/cirrhosis (Metavir stage ≥3 or Ishak stage ≥4) in order to be eligible for DAA 
treatment, despite contrary recommendations from expert committees and organizations 
(Louisiana Department of Health, 2016). For example, the most current AASLD/IDSA 
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recommendations still support treatment with DAAs for all patients chronically infected with HCV 
(genotypes 1-6) with or without cirrhosis (AASLD/IDSA, 2017). Given the many complications 
of untreated chronic HCV infection including advanced liver disease, decompensated cirrhosis, 
hepatocellular carcinoma (HCC), liver transplant, and death, early treatment and eradication of the 
virus is crucial. Early treatment of chronic HCV infection and SVR has been shown to reduce all-
cause mortality (Backus et al., 2011). Prevention of liver-related diseases may not be the only 
benefit with early HCV treatment. More recent studies seem to suggest that chronic HCV infection 
is also linked to increased subclinical cardiovascular disease (CVD) and potentially increased 
CVD outcomes (Babiker et al., 2017). More importantly, HCV treatment resulting in SVR appears 
to reduce these CVD risk, raising the importance of early treatment (Babiker et al., 2017). 
Additionally, in a cohort study, SVR after treatment has shown to reduce the incidence of onset of 
type 2 diabetes (Arase et al., 2009). 
Recent substance use 
Recent alcohol or illicit drug use was a key cause of pre-eligibility delays and recent illicit 
drug use caused significant post-eligibility delays in the study population. During a majority of the 
study period, Medicaid required patients to remain sober from alcohol and illicit drugs for 12 
months in order to be eligible for DAA treatment (Louisiana Department of Health, 2016). 
However, recent studies suggest that history of alcohol abuse should not serve as a deterrent to 
HCV treatment. In patients who were closely supported and monitored, history of high pre-
treatment alcohol consumption or failure to maintain sobriety for 6 months before treatment did 
not affect treatment completion rates or SVR (Russell et al., 2012). Furthermore, a cohort study of 
individuals with alcohol abuse/dependence revealed that chronic HCV infection significantly 
reduces survival in this group compared to those without infection (Muga et al., 2018). This 
suggests that patients with concurrent HCV infection and alcohol-abuse should be more readily 
treated, rather than delaying treatment. Towards the conclusion of the study period, effective May 
2018, Louisiana Medicaid made amendments to their reimbursement criteria, loosening 
restrictions on providers qualified to prescribe DAAs and reducing sobriety requirements 
(Louisiana Department of Health, 2018). 
Limitations 
A major limitation of this study is its generalizability outside the relatively isolated 
healthcare system of New Orleans. These findings may not be applicable to other parts of 
Louisiana, which potentially present with their own set of barriers to access. Further, low rates of 
VHC eligibility and attainment resulted in a low sample size for this study despite an extensive 
enrollment period. Given the complex psychosocial factors impacting this population’s decision 
to pursue medical care, it is difficult to isolate delays caused by institutional and policy barriers 
from social determinants. Finally, changes to Medicaid DAA policy in May 2018 may have 
impacted prescribing factors in the tail end of the study. The effects of this recent policy revision 
are yet unclear and further studies are needed to determine if this revision will truly make DAAs 
more accessible to Medicaid patients.                                  
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